1 0

    FDA ARCALYST (BLA 125249 – SUPP 49) REVIEW DOCS FOR RECURRENT PERICARDITIS APPROVAL

    FDA ARCALYST (BLA 125249 – SUPP 49) REVIEW DOCS FOR RECURRENT PERICARDITIS APPROVAL

    $69.00 USD
    $69.00 USD
    Sale Sold out
    Original Request: All Review Documents for the approval of the following indication for ARCALYST (rilonacept) (BLA 125249 – Supplement 49) approved on March 18, 2021: Treatment of recurrent pericarditis and reduction in risk of recurrence in adults and children 12 years of age and older.
    Tags: Pharma, BLA, 2021
    • Status: Pending Fast-Track Request
    • Delivery: Approximately 1 to 2 weeks when the FOIA office is operating at regular capacity

    NOTE: This document is not currently in our library. Upon purchase, we will request the document from the FDA FOIA office. Learn more about Fast-Track Requests here.

    View full details